TY - JOUR
T1 - What are the long-term symptoms and complications of COVID-19
T2 - a protocol for a living systematic review
AU - Michelen, Melina
AU - Cheng, Vincent
AU - Manoharan, Lakshmi
AU - Elkheir, Natalie
AU - Dagens, Drew
AU - Hastie, Claire
AU - O'Hara, Margaret
AU - Suett, Jake C
AU - Dahmash, Dania
AU - Bugaeva, Paulina
AU - Rigby, Ishmaela
AU - Munblit, Daniel
AU - Harriss, Eli
AU - Burls, Amanda
AU - Foote, Carol
AU - Scott, Janet
AU - Carson, Gail
AU - Olliaro, Piero
AU - Sigfrid, Louise
AU - Stavropoulou, Charitini
N1 - Copyright: © 2021 Michelen M et al.
PY - 2020
Y1 - 2020
N2 - Although the majority of people with Covid-19 will experience mild to moderate symptoms and will recover fully, there is now increasing evidence that a significant proportion will experience persistent symptoms for months after the acute phase of the illness. These symptoms include, among others, fatigue, problems breathing, lack of smell and taste, headaches, and depression and anxiety. It is also clear the virus has lasting fluctuating multiorgan sequelae, including affecting not only the respiratory system but also the heart, liver, and nervous system. We present a protocol for a living systematic review that aims to synthesize the evidence on the prevalence and characteristics of post-acute COVID-19. The living systematic review will be updated regularly, approximately every 6 months, as new evidence emerges. We will include studies that follow up at least 100 people with Covid-19 at 12 or more weeks post Covid-19 onset, with no restrictions regarding country, setting, or language. We will use descriptive statistics and, for outcomes reported in two or more studies, we will use meta-analyses to estimate prevalence with 95% confidence intervals (CIs) using the exact method. Heterogeneity between estimates will be assessed using the I2 statistic. Our findings will also be presented as infographics to facilitate transcription to lay audiences. Ultimately, we aim to support the work of policy makers, practitioners, and patients when planning rehabilitation for those recovering from Covid-19. The protocol has been registered with PROSPERO ( CRD42020211131, 25/09/2020).
AB - Although the majority of people with Covid-19 will experience mild to moderate symptoms and will recover fully, there is now increasing evidence that a significant proportion will experience persistent symptoms for months after the acute phase of the illness. These symptoms include, among others, fatigue, problems breathing, lack of smell and taste, headaches, and depression and anxiety. It is also clear the virus has lasting fluctuating multiorgan sequelae, including affecting not only the respiratory system but also the heart, liver, and nervous system. We present a protocol for a living systematic review that aims to synthesize the evidence on the prevalence and characteristics of post-acute COVID-19. The living systematic review will be updated regularly, approximately every 6 months, as new evidence emerges. We will include studies that follow up at least 100 people with Covid-19 at 12 or more weeks post Covid-19 onset, with no restrictions regarding country, setting, or language. We will use descriptive statistics and, for outcomes reported in two or more studies, we will use meta-analyses to estimate prevalence with 95% confidence intervals (CIs) using the exact method. Heterogeneity between estimates will be assessed using the I2 statistic. Our findings will also be presented as infographics to facilitate transcription to lay audiences. Ultimately, we aim to support the work of policy makers, practitioners, and patients when planning rehabilitation for those recovering from Covid-19. The protocol has been registered with PROSPERO ( CRD42020211131, 25/09/2020).
KW - Anxiety
KW - COVID-19
KW - Disease Progression
KW - Heart
KW - Humans
KW - SARS-CoV-2
U2 - 10.12688/f1000research.27284.2
DO - 10.12688/f1000research.27284.2
M3 - Article (Academic Journal)
C2 - 34621523
SN - 2046-1402
VL - 9
SP - 1455
JO - F1000Research
JF - F1000Research
ER -